Revvity to Acquire ACD/Labs
Acquisition deepens Revvity Signals’ presence in research informatics while furthering its ongoing expansion into development and manufacturing solutions
Advertisement
Revvity, Inc. announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to accelerate scientific innovation. The transaction is expected to close late in Q4 2025.
ACD/Labs brings deep expertise in supporting analytical and process chemistry within pharmaceutical and chemical R&D workflows. Its industry-leading tools help scientists identify and characterize molecules, monitor purity and quality, and deliver robust production processes. Together, Revvity Signals and ACD/Labs will provide comprehensive support across the scientific workflow—from discovery and development to scale-up and manufacturing— giving scientists the ability to interpret, manage, and act on complex data with greater speed and confidence.
“By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution,” said Kevin Willoe, president of Revvity Signals Software. “This acquisition adds meaningful value to our portfolio and reinforces the importance of analytical sciences as a driver of innovation across disciplines.”
“For more than three decades, our scientists, informaticians, and software developers have been recognized as leaders in analytical and chemical intelligence,” said Daria Thorp, president and CEO of ACD/Labs. “Joining the Revvity Signals team brings together two industry leaders with a shared commitment to innovation in scientific software. Together, we will expand the reach of our technology and deliver unified, end-to-end solutions that empower customers with deeper insight and greater scientific continuity.”
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
Last viewed contents
Scientists identify 160 new drugs that could be repurposed against COVID-19 - Forty of these drugs have already entered clinical trials
Transparency for clinical trials - Transparency of study results in a public dashboard
Bertelsmann Investments acquires stake in AI-powered Israeli healthcare startup QuantHealth - AI-supported start-up company for clinical trial planning
First synthesis of open-chain N-stereogenic amines achieved - Study enables enantiomerically pure products for drug development.
The spider with the bee venom - New perspectives for the search for active substances against cell-based diseases - Researchers decode the toxin arsenal of the most poisonous native spider species
Is the immune system younger in the morning? - The internal clock of immune cells
Pancreatic cancer forms "synapses" - Pancreatic tumors use neurotransmitters to drive their own growth: Researchers hope to identify drugs that can block this process
A toxin with a useful twist - Their work opens the door to new applications in lab-on-a-chip technologies, biosensors, and artificial cell prototypes
Gene scissors in camouflage mode help in the search for cancer therapies - Overlooked genes for metastasis formation uncovered
Gene modification enables more functional liver cells from stem cells
Bacteria Borrow Viruses to Spread Their Own Defences - Pseudomonas fluorescens exposed to sterile compost filtrate acquired multiple mobile genetic elements carrying anti-phage defence genes
